about
Lupus mastitis: a mimicker of breast carcinomaPreventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) studyA consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modificationsRecommendations for the use of icodextrin in peritoneal dialysis patients.A review of the current treatment of renal artery stenosis.n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney DiseaseOptimal use of plasma and urine BK viral loads for screening and predicting BK nephropathy.HLA donor-specific antibody detected by solid phase assay identifies high-risk transplantation pairs irrespective of CDC crossmatch results: case reports and literature review.Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial.Insulin resistance and vascular dysfunction in chronic kidney disease: mechanisms and therapeutic interventions.CMV drives the expansion of highly functional memory T cells expressing NK-cell receptors in renal transplant recipients.Changing survival of people with myeloma and end stage kidney disease; a cohort study using ANZDATA 1963-2013.Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology.Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial.Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD.Infectious complications in indigenous renal transplant recipients in Western Australia.Cytomegalovirus infection alters phenotypes of different γδ T-cell subsets in renal transplant recipients with long-term stable graft function.Asymptomatic CMV infections in long-term renal transplant recipients are associated with the loss of FcRγ from LIR-1+ NK cells.Cytomegalovirus antibody and vascular pathology in renal transplant recipients.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.The effect of genetic variants affecting NK cell function on cardiovascular health and the burden on CMV.Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant.The Relationship Between Presentation and the Time of Initial Administration of Antibiotics With Outcomes of Peritonitis in Peritoneal Dialysis Patients: The PROMPT Study.Vascular function of the peripheral circulation in patients with nephrosis.Insulin resistance and the metabolic syndrome are associated with arterial stiffness in patients with chronic kidney disease.Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.Estimation of glomerular filtration rate: does haemoglobin discriminate between ageing and true CKD?Statin therapy improves brachial artery endothelial function in nephrotic syndrome.Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study.Anemia after kidney transplantation is not completely explained by reduced kidney function.Insulin resistance, dyslipidaemia, inflammation and endothelial function in nephrotic syndrome.Presentation and survival of patients with severe renal failure and myeloma.Rosiglitazone does not improve vascular function in subjects with chronic kidney disease.HLA antibodies and soluble CD30 are associated with poor renal graft outcome: updated results of a single-center cross-sectional study.Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function.Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients.Effect of ascorbic acid supplementation on plasma isoprostanes in haemodialysis patients.The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled.
P50
Q30445572-E037E88D-B1E0-4BAA-8D69-E253283EB156Q33401679-4BA8041A-0D87-40CB-8283-1606A07D6344Q35149475-48094F90-F5B8-4779-959E-BE2281E9EF4DQ35676161-75E42C9F-BEFB-4411-A26F-D01CF8AF2B8DQ35687644-6C2CFF59-5DAC-40A8-9C91-6F0745387D07Q36167932-589F9D67-633D-4341-8F6D-7D301A86B7FDQ36732191-EA512A0C-D66F-4D7C-AB3C-3CB717AD62FBQ37118018-DE6CBDCA-B351-4EA7-92B2-948139D2E4C8Q37118654-49ABB5B2-9484-482E-88B6-4A9BD6EBAD11Q38026511-DCDA7174-D1E9-4A0E-B97F-26B83DB5D04AQ38382811-BC8B31BD-A8E6-4659-89AD-51E8C826437EQ38587721-C9E545EF-DAAE-47E3-9BA0-0C501117B6ECQ38741001-1AC1A52D-7F3A-49B3-8870-D56E4C62A8A0Q39075936-F1E347A4-5C69-455B-8FA3-08694FEDF308Q39464110-774B5486-1471-49DE-A4A3-2666ED1B6FA3Q40141033-26BE9C39-A09D-4CAE-BC60-06545BF92B21Q40261437-C7253054-81D0-4B4B-ADAD-B2AC611BA976Q40266995-B7BE474F-4CA0-4035-A38D-0FBB876D1F75Q40332777-854644FA-17CE-421A-A426-2CF032F058BBQ40467077-2E386050-2D08-4C00-AC38-44DA24401B34Q40473869-E7DA61F9-E68F-4592-B035-2BAA6C8EB625Q41553370-CE47513E-E300-403D-80FC-9964676F34AEQ41990028-41F75D24-D4CB-4BD3-BD70-9585019DC384Q42840200-B227C268-31E1-4753-9167-9A5490DFA0CBQ43488863-AB933F51-0C32-4FC0-88DB-C591E928A7A5Q43651219-F2231B34-1174-46DC-B294-8542C65CB79FQ43660294-EB6C07FD-66A0-4026-8398-3AA87B7B7DFEQ43829027-435914AE-6728-4CA3-B533-E66C19DA9CAEQ44025768-B024BB1A-55DC-40C0-AE88-5896BC4D05E4Q44057563-62E9607A-0844-4872-8395-3A7DF62657A7Q44077390-9EF4F332-AFBE-4D53-804C-6B766B9D2051Q44079514-1F2D29FF-FC53-4F6F-B714-3A68D8F4D799Q44231183-6268B07D-4F34-4E57-A671-B9C5D6BC6CEAQ44399448-DEC8652D-8B62-444E-98E9-D01687D466AEQ44983950-F63FF831-78C2-4D17-8294-75372F90EC2FQ45238201-CDA8C179-A86F-4D1F-B647-E4082E2EB044Q46590799-AE4C9481-714E-4774-86FB-BE45FE1673F9Q46657532-8E273316-2187-4808-A38D-3AF87C0F7E95Q46735408-7AE59850-E132-4D60-9746-93FA68268C12Q47282789-818DE691-1C70-4D4A-AE43-14205D970AC9
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ashley B. Irish
@ast
Ashley B. Irish
@en
Ashley B. Irish
@es
Ashley B. Irish
@nl
Ashley B. Irish
@sl
type
label
Ashley B. Irish
@ast
Ashley B. Irish
@en
Ashley B. Irish
@es
Ashley B. Irish
@nl
Ashley B. Irish
@sl
prefLabel
Ashley B. Irish
@ast
Ashley B. Irish
@en
Ashley B. Irish
@es
Ashley B. Irish
@nl
Ashley B. Irish
@sl
P106
P1153
7004314741
P21
P31
P496
0000-0002-9577-3764